Opportunity Information: Apply for HRSA 14 078
Apply for HRSA 14 078
- The Health Resources and Services Administration in the health sector is offering a public funding opportunity titled "Sickle Cell Disease Treatment Demonstration Program Regional Collaborative" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.365 Sickle Cell Treatment Demonstration Program.
- This funding opportunity was created on Apr 25, 2014 and posted on Apr 24, 2014.
- Applicants must submit their applications by May 27, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,400,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $850,000.00 in funding.
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligible entities for this cooperative agreement program are any Federally qualified health center, nonprofit hospital or clinic, or university health center that provides primary health care that (1) has a collaborative agreement with a community based sickle cell disease organization or a nonprofit entity with experience in working with individuals with sickle cell disease and (2) demonstrates that it, the collaborative entity, or the experts described in section 712(c)(2)(C) of the American Jobs Creation Act of 2004, has at least five (5) years experience working with individuals who have sickle cell disease. Faith based and community based organizations that meet these qualifications are eligible.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Sickle Cell Disease Treatment Demonstration Program Regional Collaborative (HRSA-14-078) is a Health Resources and Services Administration (HRSA) discretionary funding opportunity offered as a cooperative agreement to build stronger, better coordinated regional systems of care for people living with sickle cell disease. The program is designed around the idea that sickle cell outcomes improve when more frontline clinicians are prepared to manage the condition, when evidence-based disease-modifying therapies are used more consistently, and when patients can access providers and services that understand the full clinical and supportive-care needs associated with sickle cell disease. In practical terms, the grant focuses on expanding provider capacity and improving the quality and continuity of care across a region, rather than supporting isolated activities at a single site.
The core purpose of the opportunity is threefold: first, to increase the number of providers in a region who actively treat sickle cell patients; second, to increase the number of providers who prescribe disease-modifying therapies, specifically naming hydroxyurea as an example; and third, to increase the number of sickle cell patients receiving care from clinicians with stronger knowledge and skills in sickle cell treatment. HRSA frames these aims as a workforce and system-development problem, meaning the program is not only about direct clinical services, but also about building the infrastructure, partnerships, training pipelines, and shared practices that make high-quality sickle cell care more available and consistent across settings.
A major feature of the program is its emphasis on forming Sickle Cell Regional Collaboratives that use collective impact strategies and collaborative learning. This signals that HRSA expects applicants to convene multiple stakeholders who share a common agenda and use coordinated approaches rather than operating in silos. The collaboratives are intended to create or strengthen regional and state-level infrastructure that supports broader uptake of disease-modifying therapy and strengthens prevention and treatment efforts. Activities highlighted in the announcement include coordinating service delivery across providers and organizations, improving access to genetic counseling and testing, bundling technical services that individual clinics may not be able to provide alone, and expanding training opportunities for health professionals. The program also emphasizes education, treatment coordination, and continuity of care, reflecting the reality that people with sickle cell disease often need consistent, longitudinal management across primary care, specialty care, emergency care, and community-based supports.
Funding for the opportunity was estimated at $3.4 million total, with an expectation of four awards. The award ceiling was listed at $850,000, and there was no cost sharing or matching requirement. The opportunity was posted on April 24, 2014, with an application closing date of May 27, 2014, and it was later archived on July 26, 2014. The applicable CFDA number for the program is 93.365 (Sickle Cell Treatment Demonstration Program), which helps identify the federal assistance program under which the awards are made.
Eligibility is targeted to organizations that can provide primary health care and also demonstrate strong, established connections to the sickle cell community. Eligible applicants include Federally Qualified Health Centers, nonprofit hospitals or clinics, and university health centers that provide primary health care. A key requirement is that the applicant must have a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity experienced in working with individuals with sickle cell disease. In addition, the applicant (or its collaborative partner, or the relevant experts referenced in the authorizing statute) must demonstrate at least five years of experience working with people who have sickle cell disease. Faith-based and community-based organizations can be eligible as well, as long as they meet these qualifications. Overall, HRSA is signaling that applicants should not be new to sickle cell work and should already have meaningful, durable relationships with community stakeholders.
Because this is a cooperative agreement, recipients should generally expect substantial federal involvement compared to a more hands-off grant mechanism. While the summary text does not detail specific roles, cooperative agreements typically involve closer collaboration with HRSA on implementation, performance expectations, and learning activities. The announcement also points applicants to HRSA support resources through the HRSA Grants Application Center and HRSA Call Center for help accessing the full announcement and addressing submission or technical issues.
Frequently Asked Questions (FAQs)
What is the Sickle Cell Disease Treatment Demonstration Program Regional Collaborative (HRSA-14-078)?
HRSA-14-078 is a Health Resources and Services Administration (HRSA) discretionary funding opportunity offered as a cooperative agreement. Its focus is to build stronger, better coordinated regional systems of care for people living with sickle cell disease by expanding provider capacity and improving the quality and continuity of care across a region.
What is the main goal of this program?
The program is intended to improve sickle cell outcomes by strengthening regional care systems. It emphasizes preparing more frontline clinicians to manage sickle cell disease, increasing consistent use of evidence-based disease-modifying therapies, and improving patient access to providers and services that understand both clinical needs and supportive-care needs.
What are the program's three core purpose areas?
The opportunity identifies three core aims: (1) increase the number of providers in a region who actively treat sickle cell patients; (2) increase the number of providers who prescribe disease-modifying therapies (hydroxyurea is specifically named as an example); and (3) increase the number of sickle cell patients receiving care from clinicians with stronger knowledge and skills in sickle cell treatment.
Is this funding meant to support direct clinical services at a single site?
The grant is framed as a workforce and system-development effort. In practical terms, it prioritizes expanding provider capacity and improving regional quality and continuity of care rather than supporting isolated activities at a single site.
What is a Sickle Cell Regional Collaborative in this program?
A Sickle Cell Regional Collaborative is a multi-stakeholder group expected to work together using collective impact strategies and collaborative learning. The intent is to coordinate approaches across organizations instead of operating in silos and to create or strengthen regional and state-level infrastructure that improves sickle cell prevention and treatment efforts.
What kinds of activities does HRSA highlight for the collaboratives?
Highlighted activities include coordinating service delivery across providers and organizations, improving access to genetic counseling and testing, bundling technical services that individual clinics may not be able to provide alone, and expanding training opportunities for health professionals. The program also emphasizes education, treatment coordination, and continuity of care.
Why does the program focus on regional coordination and continuity of care?
The opportunity reflects that people with sickle cell disease often need consistent, longitudinal management across primary care, specialty care, emergency care, and community-based supports. The regional approach is intended to make care more available and consistent across settings.
What is meant by "disease-modifying therapies" in this opportunity?
The opportunity calls for increased prescribing of disease-modifying therapies and specifically names hydroxyurea as an example. The program aims to support broader uptake and consistent use of these therapies through regional systems and provider capacity-building.
What type of award mechanism is used (grant vs. cooperative agreement)?
This opportunity is offered as a cooperative agreement. The summary indicates that recipients should generally expect substantial federal involvement compared to a more hands-off grant mechanism, typically implying closer collaboration with HRSA on implementation and learning activities.
How much funding was available under this opportunity?
Total estimated funding was $3.4 million, with an expectation of four awards.
What was the maximum award amount per recipient?
The award ceiling was listed at $850,000.
Was cost sharing or matching required?
No cost sharing or matching requirement was listed.
When was the opportunity posted and when were applications due?
The opportunity was posted on April 24, 2014, and the application closing date was May 27, 2014.
Is this funding opportunity still open?
No. The opportunity was later archived on July 26, 2014.
What is the CFDA number for this program?
The applicable CFDA number is 93.365, identified as the Sickle Cell Treatment Demonstration Program.
Who is eligible to apply?
Eligibility is targeted to organizations that can provide primary health care and can demonstrate strong, established connections to the sickle cell community. Eligible applicants include Federally Qualified Health Centers, nonprofit hospitals or clinics, and university health centers that provide primary health care.
Are faith-based or community-based organizations eligible?
Faith-based and community-based organizations can be eligible as well, as long as they meet the stated qualifications, including the primary health care focus and the required connections and experience related to sickle cell disease.
Is a partnership with a community-based sickle cell organization required?
Yes. A key requirement is that the applicant must have a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity experienced in working with individuals with sickle cell disease.
Is there a minimum experience requirement related to sickle cell disease?
Yes. The applicant (or its collaborative partner, or the relevant experts referenced in the authorizing statute) must demonstrate at least five years of experience working with people who have sickle cell disease.
What does HRSA mean by "strong, established connections to the sickle cell community"?
The opportunity emphasizes that applicants should not be new to sickle cell work and should already have meaningful, durable relationships with community stakeholders, reinforced by the requirement for a collaborative agreement and the five-year experience expectation.
Where can applicants find help or support resources related to this opportunity?
The announcement points applicants to support resources through the HRSA Grants Application Center and the HRSA Call Center for help accessing the full announcement and addressing submission or technical issues.
What is the program trying to change in the health care workforce?
HRSA frames the aims as a workforce and system-development problem. The program is designed to increase the number of providers actively treating sickle cell patients, increase the number prescribing disease-modifying therapies, and strengthen clinician knowledge and skills so more patients receive care from well-prepared providers.
Browse more opportunities from the same category: Health
Next opportunity: California Landscape Conservation Cooperative
Previous opportunity: Emerging Pandemic Threats Program 2, PREDICT 2
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for HRSA 14 078
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (HRSA 14 078) also looked into and applied for these:
| Funding Opportunity |
|---|
| Immunization Information Systems (IIS) Capacity Building Apply for CDC RFA IP12 120103CONT14 Funding Number: CDC RFA IP12 120103CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Partner and Implement Public Health Strategies Related to Apply for CDC RFA DP10 100305CONT14 Funding Number: CDC RFA DP10 100305CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Planning Grant for Global Infectious Disease Research Training Program (D71) Apply for PAR 14 194 Funding Number: PAR 14 194 Agency: National Institutes of Health Category: Health Funding Amount: $28,000 |
| Global Infectious Disease Research Training Program (D43) Apply for PAR 14 193 Funding Number: PAR 14 193 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV/AIDS Initiative for Minority Men (AIMM) Apply for MP CPI 14 002 Funding Number: MP CPI 14 002 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $375,000 |
| Centers of Excellence in Genomic Science (CEGS) (RM1) Apply for PAR 14 195 Funding Number: PAR 14 195 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Morris K. Udall Centers of Excellence for Parkinsons Disease Research (P50) Apply for RFA NS 14 003 Funding Number: RFA NS 14 003 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Economic Studies of Vaccines and Immunization Policies, Programs, and Practices for Adults Apply for CDC RFA IP14 1403 Funding Number: CDC RFA IP14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $150,000 |
| Voluntary Medical Male Circumcision (VMMC), Early Infant Circumcision (EIMC) Service Delivery and Support to the Government of the Kingdom of Swaziland Apply for RFA 674 14 000001 Funding Number: RFA 674 14 000001 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $24,500,000 |
| Disseminating and Implementing Evidence from Patient Centered Outcomes Research in Clinical Practice Using Mobile Health Technology (R21) Apply for RFA HS 14 010 Funding Number: RFA HS 14 010 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $150,000 |
| Emerging Pandemic Threats Program 2, Preparedness Apply for RFA OAA 14 000020 Funding Number: RFA OAA 14 000020 Agency: Agency for International Development Category: Health Funding Amount: $45,000,000 |
| Bridging the Word Gap Research Network Apply for HRSA 14 131 Funding Number: HRSA 14 131 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R41/R42) Apply for PA 14 196 Funding Number: PA 14 196 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R43/R44) Apply for PA 14 197 Funding Number: PA 14 197 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| EPT 2, One Health Workforce Apply for RFA OAA 14 000023 Funding Number: RFA OAA 14 000023 Agency: Agency for International Development Category: Health Funding Amount: $50,000,000 |
| American Indians Into Medicine Apply for HHS 2014 IHS INMED 0001 Funding Number: HHS 2014 IHS INMED 0001 Agency: Indian Health Service Category: Health Funding Amount: $195,000 |
| Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R01) Apply for PA 14 198 Funding Number: PA 14 198 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAMS Clinical Trial Implementation Cooperative Agreement (U01) Apply for PAR 14 200 Funding Number: PAR 14 200 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAMS Clinical Trial Planning Cooperative Agreement (U34) Apply for PAR 14 199 Funding Number: PAR 14 199 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Sudden Death in the Young (SDY) Registry Apply for CDC RFA DP14 1403 Funding Number: CDC RFA DP14 1403 Agency: NCCDPHP Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "HRSA 14 078", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.